中国脑淀粉样血管病诊治共识(2023版)  

Chinese consensus on the diagnosis and management of cerebral amyloid angiopathy(2023 edition)

作　　者：中华医学会神经病学分会 中华医学会神经病学分会脑血管病学组 倪俊[2] 彭斌[2] 王拥军[3] Chinese Society of Neurology;Chinese Stroke Society;Ni Jun;Peng Bin;Wang Yongjun(不详;Department of Neurology,Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,China National Clinical Research Center for Neurological Diseases,Beijing 100070,China)

机构地区：[1]不详 [2]中国医学科学院北京协和医院神经科,北京100730 [3]首都医科大学附属北京天坛医院神经内科、国家神经系统疾病临床医学研究中心,北京100070

出　　处：《中华神经科杂志》2024年第10期1051-1074,共24页Chinese Journal of Neurology

摘　　要：脑淀粉样血管病(CAA)是一类由β淀粉样蛋白沉积在大脑皮质和软脑膜小血管导致的年龄相关脑小血管病。为提高临床医生对CAA的认识和诊治水平,促进临床实践的标准化,中华医学会神经病学分会及其脑血管病学组制订了本共识。共识基于当前国内外最佳研究证据,采用证据质量和推荐分级的评估、制订与评价系统,衡量安全性、有效性、可行性等因素后形成推荐意见,回答了14个有关CAA的诊断、治疗等方面的临床问题,目的是指导临床医生规范诊治CAA。Cerebral amyloid angiopathy(CAA)is an age-related cerebral small vessel disease caused by amyloid-βdeposition in the wall of cortical and leptomeningeal small vessels.In order to further improve the understanding of clinical diagnosis and treatment of CAA,and promote the standardization of clinical practice,the Chinese Society of Neurology and Chinese Stroke Society have formulated the present consensus.Based on recent high-quality studies,this consensus adopts the grading of recommendations assessment,development and evaluation system,comprehensively weighing safety,efficacy,feasibility and other factors to form corresponding recommendations for 14 clinical issues of great concern on CAA clinical diagnosis,treatment,prognosis evaluation,etc.The ultimate goal of this consensus is to provide guidance to standardize the diagnosis and treatment of CAA in China.

关 键 词：脑淀粉样血管病 诊断 治疗 共识 

分 类 号：R743[医药卫生—神经病学与精神病学]